In-depth articles on addiction treatment, recovery science, and what day-to-day care actually looks like — written by the people who deliver it.
From the paperwork to the evaluation to walking out with a treatment plan — here is exactly how a first Suboxone visit works at our clinics. We walk you through each stage so you know what to expect before you walk through the door.
Read full article →
Physical, behavioral, and emotional signs of opioid dependence, mapped to the clinical criteria doctors use. A family-first guide to recognizing when MAT may help and what to do next.
Read article →
Recognizing the early warning signs of opioid dependence can be the first step toward recovery. Here is what to look for.
Read article →
A look at the evidence behind medication-assisted treatment and how it compares to abstinence-only approaches to addiction recovery.
Read article →
What outpatient treatment looks like day-to-day — scheduling, structure, and what to expect from programs like MAT and IOP.
Read article →
A plain-language day-by-day timeline of kratom (and 7-OH) withdrawal, the symptoms most patients report, when medical help matters, and why MAT works for kratom dependence.
Read article →
Why buprenorphine-based MAT works for kratom and 7-OH dependence, what induction timing looks like, dose ranges, and what starting Suboxone actually involves.
Read article →
A receptor-level explainer: buprenorphine at the mu-opioid receptor, why partial agonism produces a ceiling effect, PET-imaged receptor occupancy (36-50% at 2mg, 79-95% at 16mg), reward-pathway recovery during stable MAT, and why the “trading one addiction for another” frame misunderstands the pharmacology.
Read article →
The pharmacology of concentrated 7-hydroxymitragynine, why it’s more potent than leaf kratom, the FDA July 2025 Schedule I recommendation, and clinical implications.
Read article →
Short answer as of April 24, 2026: no, 7-OH is not federally scheduled. The FDA recommended Schedule I on July 29, 2025; the DEA is still reviewing with no proposed rule published. Timeline, state-level picture, and what it means for treatment.
Read article →
When a self-directed kratom taper can realistically work, when it fails, a reasonable protocol if you’re trying one, and when medication-assisted treatment is the safer path.
Read article →
Tennessee’s kratom ban (HB1649/SB1656) passed both chambers April 16, 2026 and awaits the Governor’s signature — if signed, TN becomes the 8th state to fully ban kratom (effective July 1, 2026). Class A misdemeanor possession, Class C felony manufacture/sale. HB2594 (the regulate alternative) did not advance.
Read article →
Where kratom law stands in every U.S. state as of April 2026: 7 fully-banned states (AL, AR, IN, LA, VT, WI, CT), Rhode Island’s first-ever ban reversal, 30+ states with Kratom Consumer Protection Act regulation, pending 2026 ban bills in TN, GA, SC, WA, MI, and more. What any state’s status means for treatment access.
Read article →
The data-table companion to our TennCare MAT pillar: 7 tables covering covered medications and PA rules, the three MCOs side by side (BlueCare, UHC Community Plan, Wellpoint), BESMART vs. non-BESMART, telehealth under the 2026 DEA permanent buprenorphine rule, hepatitis C DAA coverage (Epclusa + Mavyret), and what TennCare members typically pay.
Read tracker →
The five MAT medications offered at Restoration Recovery in two scannable tables: clinical profile (mechanism, route, dose, frequency, ceiling effect, initiation) and practical profile (prior auth, take-home factor, telehealth-friendly, switching pathway). Plus short, honest descriptions of which patient situation each medication is built for.
Read comparison →
The two federally regulated MAT pathways — office-based prescribing (OBOT) under DEA registration and SAMHSA-certified opioid treatment programs (OTPs) under 42 CFR Part 8. How the MAT Act 2023 + DEA permanent buprenorphine telehealth rule reshaped office-based access, and which pathway fits which patient profile.
Read comparison →
A medication-level comparison: full mu-agonist methadone vs partial mu-agonist Suboxone (buprenorphine + naloxone). Pharmacology, ceiling effects, retention data from Mattick 2014 Cochrane, mortality reduction from Sordo 2017 BMJ, safety profile differences, and which medication fits which patient situation — including pregnancy, fentanyl-using patients, and chronic pain.
Read comparison →
Yes — but timing matters more for 7-OH than for most substances. The clinical wait window, why 7-OH is harder to predict than leaf kratom, and what micro-induction is.
Read article →
Eight clinical markers of kratom dependence — from dose escalation to hours-after withdrawal — that our providers actually look for during intake, in patient-voice language.
Read article →
When telehealth works for kratom and 7-OH treatment, when an in-person visit is required, and what the hybrid model (one in-person, rest virtual) actually looks like.
Read article →
Short answer as of April 2026: yes for adults 21+ — but HB1649/SB1656 just passed both chambers April 16, 2026 and awaits Gov. Lee’s signature (effective July 1, 2026 if signed). If signed, Tennessee becomes the 8th state to fully ban kratom. Current law, what just happened, federal 7-OH context.
Read article →
Georgia regulates kratom under the 2019 Kratom Consumer Protection Act as amended by HB181 (age 21+, labeling, 7-OH caps). HB757 added processor registration. HB968 proposes a Schedule I ban. What Ringgold-area patients should know about the law and about treatment.
Read article →
Alabama classified mitragynine and 7-OH as Schedule I in 2016; in March 2026 the Attorney General issued a statewide cease-and-desist targeting retailers. What the ban covers, the criminal penalties, and how AL patients access MAT for kratom dependence.
Read article →
Kratom withdrawal isn’t usually medically dangerous, but it’s often more intense than patients expect — and for 7-OH concentrates, it can put people in the ER. The actual risk factors and when to stop trying to do it alone.
Read article →
Kratom use during pregnancy carries real risks — and so does cold-turkey stopping. The clinical picture, why buprenorphine in pregnancy is often the safer path, and how OB coordination works.
Read article →
Tennessee SUDORS data shows fentanyl in 66–87% of kratom-involved fatal overdoses every year since 2019. Why the combination is pharmacologically deadlier, contamination risk, and what naloxone does.
Read article →
18% of kratom ER visits in Tennessee involve a mental health event. The self-medication trap, what withdrawal does to anxiety and depression, and why integrated care works better than separate tracks.
Read article →
Sublocade delivers the same buprenorphine as Suboxone but as a once-monthly injection. For kratom patients whose pattern involved constant dosing, removing the daily decision is often what makes it stick.
Read article →
Leaf powder, capsules, 5x/10x extracts, tinctures, tablets, gummies, 7-OH concentrates — not different grades of the same product. Pharmacology, addiction profiles, and legal statuses compared.
Read article →Same-week appointments available. Most major insurance plans accepted. Call us directly or submit a request and we'll follow up within one business day.
